NCT05316493View on ClinicalTrials.gov

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Atypical Endometrial HyperplasiaFertility IssuesOverweight and Obesity
Interventions
BEHAVIORAL

Intensive Lifestyle Intervention (ILI)

dietary guidance, exercise guidance, lifestyle intervention

DRUG

Megestrol Acetate 160 MG Oral Tablet

enrolled participants will take Megestrol Acetate 160mg daily

DRUG

Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg

enrolled patients will be treated with LNG-IUS.

Trial Locations (1)

Unknown

RECRUITING

Obstetrics and Gynecology Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Xiaojun Chen

OTHER